par8o Launches Research Network
par8o has announced the launch of par8o Research Network (PRN), a clinical trial recruitment service that connects health center patients with nearby trials. To ensure both HIPAA and ethical compliance, par8o’s patient outreach and engagement protocol has been reviewed and approved by an independent Institutional Review Board, WCG IRB. With the launch of PRN, par8o will apply its knowledge to solve a major issue in clinical trials—specifically, the lack of racial, ethnic, and socioeconomic diversity.
“The lack of diversity in clinical research not only increases drug costs due to failed recruitment targets and delayed timelines, but also creates an ongoing legacy of healthcare injustice against minority groups,” said par8o CEO, Dr. Daniel Palestrant, MD. “It’s well known that different racial and ethnic groups can respond differently to the same treatments. Under-representation of minority groups in a clinical trial can create a legacy of bad data, which can ultimately impact patient access to therapeutics. We are confident that PRN will move the needle on the lack of diverse racial and ethnic representation in clinical trials.”
Read more in the full release, here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
